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Introduction: Dilated cardiomyopathy is a severe condition in which the heart muscle is 
weakened and no longer has the strength to pump blood throughout the body. The weakened heart 
is unable to pump more blood, therefore more blood remains to this level after each heartbeat. As 
larger amounts o f  blood remain in the lower chambers o f  the heart, they expand. Over time, the 
heart muscle loses its shape and becomes increasingly weaker.
Objectives: Study o f  clinical evolution and ECG o f  patients diagnosed with associated dilated 
cardiomyopathy or ALCAPA Syndrome from a basic treatment with IEC, diuretics and B-blocking 
agents along with the surgical treatment.
Materials and Methods: 10 children o f  which 9 diagnosed with dilated cardiomyopathy and 
1 child who associates ALCAPA syndrome were evaluated by Ross score, NYHA and 
échocardiographie. Cardiac index measurement using ECG and CT after receiving basic treatment.
Results: The 9 patients with dilated cardiomyopathy treated by the basic therapeutic method 
have evolved to improve cardiac indexes (Ross and NYHA) showing an increase in left ventricular 
ejection fraction gather up 20%. The patient with dilated cardiomyopathy and ALCAPA syndrome 
showed no improvement following therapy being directed to surgical treatment.
Conclusions: Dilated cardiomyopathies in pediatric age have an 80% response rate to basic 
treatment with IEC, diuretics and B-blockers that lead to Ross and NYHA amelioration. Dilated 
cardiomyopathy associated with ALCAPA syndrome has one treatment option: heart transplant.
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Introduction: Graves’ orbitopathy (GO) constitutes a major clinical and therapeutic 
challenge. GO is an autoimmune disorder representing the most common and most important 
extrathyroidal manifestation o f  Graves’ disease. Although the pathogenesis o f  GO is beyond the 
scope o f this study, attention is drawn to the link between the orbit and thyroid, which has important 
clinical and therapeutic implications. Optimal management o f  GO requires a coordinated approach 
addressing the thyroid dysfunction and the orbitopathy.
Purpose and Objectives: To establish the relationship between Graves’ disease evolution and the 
onset of ocular manifestations. To evaluate the activity and severity o f  GO in our study group.
Materials and Methods: This study is based on the clinical examination o f  16 patients, using 
the Clinical Activity Score (CAS) and the NOSPECS classification o f  the disease’s severity.
Results: During this study, we have seen 16 patients (32 eyes). 12 o f  these patients presented 
bilateral involvement, while 4 -  unilateral involvement. We have studied the onset o f  Graves’ 
orbitopathy in relation to the onset o f  hyperthyroidism, and w e’ve determined that most commonly 
GO occurs at the same time or follows the hyperthyroidism (up to 81% o f  cases). The activity o f  
GO was determined using CAS. W e’ve determined that the spontaneous orbital pain, gaze evoked 
orbital pain, conjunctival redness and the eyelid swelling were the most common manifestations 
presented by our patients (50-75%  o f  cases), while eyelid erythema was the less common (12.5%). 
The frequency o f  active and inactive cases was almost equal, with a minor prevalence o f  active 
processes. The disease’s severity was appreciated using NOSPECS classification. Most patients 
presented a minimal grade o f  severity (43.7% -  7 patients), while 37.5% (6 patients) have presented 
a moderate grade and only 18.8% (3 patients) -  maximal severity. The first two classes o f  the
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